Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody

American Journal of Hematology

Volumn 77, Issue 4, 2004, Pages 346-350

  Monahan, Paul E ^a   Aledort, Louis M ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

aPCC; Factor IX; Factor VIII; Inhibitor; Recombinant factor VIIa

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; HEMOSTATIC AGENT; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ANTIBODY TITER; ARTICLE; COST BENEFIT ANALYSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG CHOICE; DRUG SAFETY; HEART INFARCTION; HEMOPHILIA; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; THROMBOSIS;

ANTIBODIES; ANTIBODY FORMATION; BLOOD COAGULATION FACTORS; COST-BENEFIT ANALYSIS; FACTOR VIIA; FACTOR VIII; HEMOPHILIA A; HUMANS; RECOMBINANT PROTEINS;

EID: 9644259311     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20204     Document Type: Article

References (27)

1. nd, Rosendaal F, Aledort LM, et al. Definitions in Hemophilia. Recommendations of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 2001;85:560.
2. Tarantino M, Aledort L. On the treatment of hemorrhage in patients with hemophilia and associated inhibitors. Transfusion 2001;41:1628-1629.
3. Kulkarni R, Aledort LM, Berntorp E, et al. Therapeutic choices for patients with hemophilia and high-liter inhibitors. Am J Hematol 2001;67:240-246.
4. Jones ML, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors. Haemophilia 2003;9:464-520.
5. Lee CA. The evidence behind inhibitor treatment with porcine factor VIII. Pathophysiol Haemost Thromb 2002;32(Suppl 1):5-8.
6. Teitel JM. Recombinant factor Vila versus aPCCs in haemophiliacs with inhibitors. Treatment and cost considerations. Haemophilia 1999;5(Suppl 3):43-49.
7. Farrugia A. Evolving perspectives in product safety for haemophilia. Haemophilia 2002;8:236-243.
8. Llewelyn CA, Hewitt PE, Knight RSG, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004;363:417-421.
9. Leissinger CA. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia 1999;5(Suppl 3):25-32.
10. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA(R)): 10-year compilation of thrombotic adverse events. Haemophilia 2002;8:83-90.
11. White II GC. Seventeen years' experience with Autoplex®/ Autoplex®-T: evaluation of inpatients with severe haemophilia A and factor VIII inhibitors at a major haemophilia centre. Haemophilia 2000;6:508-512.
12. rd, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol 2004;41(Suppl 1):101-108.
13. Ingerslev J, Holm M, Christiansen K, Knudsen L, Negrier C. Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency. Blood Coagul Fibrinolysis 1998;9(Suppl 1):S129-S134.
14. Key NS, Christie B, Henderson N, Nelsestuen GL. Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy. Thromb Haemost 2002;88:60-65.
15. rd, Roberts HR, Hoffman M. The effect of factor X level on thrombin generation and the procoagulant effect of activated factor VIIa in a cell-based model of coagulation. Blood Coagul Fibrinolysis 2000;11(Suppl):S3-S7.
16. Hough RE, Hampton KK, Preston FE, Channer KS, West J, Makris M. Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors. Br J Haematol 2000;111:974-979.
17. Rosenfeld SB, Watkinson KK, Thompson BH, Macfarlane DE, Lentz SR. Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient. Thromb Haemost 2002;87:925-926.
18. Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol 1999;104:22-26.
19. Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novo-seven) in haemophiliacs with inhibitors. Thromb Haemost 1998;6:912-918.
20. Cooper HA, Jones CP, Campion E, Roberts HR, Hedner U. Rationale for the use of high-dose rFVIIa in a high-litre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia 2001;7:517-522.
21. O'Connell N, McMahon C, Smith J, Khair K, Hann I, Liesner R, Smith OP. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors. Haemophilia 2002;116:632-635.
22. Lisman T, Mosnier LO, Lambert T, et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 2002;99:175-179.
23. Kjalke M, Ezban M, Monroe DM, Hoffman M, Roberts HR, Hedner U. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol 2001;114:114-120.
24. He S, Blomback M, Jacobsson Ekman G, Hedner U. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 2003;1:1215-1219.
25. Turacek PL, Varadi K, Gritsch H, et al. Factor Xa and prothrombin: Mechanism of action of FEIBA. Vox Sang 1999;77:72-79.
26. Turacek PL, Varadi K, Keil B, et al. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb 2003;33:16-22.
27. Tomokiyo K, Nakatomi Y, Araki T, et al. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone. Vox Sang 2003;85:290-299.